Malignant melanoma. Diagnosis and therapy;Malignes melanom. Diagnostik und therapie

HNO

Volumn 53, Issue 11, 2005, Pages 928-939

  Schultz, E S ^a,c   Schuler, G ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Excision; Immunotherapy; Malignant melanoma; Melanocytes; Metastases

Indexed keywords

AMIDE; BCG VACCINE; CANVAXIN; CARBOPLATIN; CELPENE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUDARABINE; FOTEMUSTINE; GANGLIOSIDE GM2; HISTAMINE; IMIDAZOLE; IMIQUIMOD; INTERLEUKIN 2; MELPHALAN; METHYLTRIAZINE; OBLIMERSEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; TEMOZOLOMIDE; TRIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; VISCUM ALBUM EXTRACT;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; FAMILY HISTORY; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; HYPERTHERMIA; IMMUNOTHERAPY; LIGHT EXPOSURE; LYMPH NODE DISSECTION; MALIGNANT LENTIGO; MELANOMA; METASTASIS; NEUTROPENIA; NEVUS; RISK FACTOR; SKIN; SKIN PIGMENTATION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION;

COMBINED MODALITY THERAPY; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; SKIN; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 27744532371     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-005-1326-y     Document Type: Article

References (30)

1. Wiecker TS, Luther H, Buettner P, Bauer J, Garbe C (2003) Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer 97: 628-638
2. MacKie RM, Freudenberger T, Aitchison TC (1989) Personal risk-factor chart for cutaneous melanoma. Lancet 2: 487-490
3. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
4. Kittler H, Pehamberger H, Wolff K, Binder M (2002) Diagnostic accuracy of dermoscopy. Lancet Oncol 3: 159-165
5. Bong JL, Herd RM, Hunter JA (2002) Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 46: 690-694
6. Veronesi U, Cascinelli N (1991) Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 126: 438-441
7. Ringborg U, Andersson R, Eldh J et al. (1996) Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 77: 1809-1814
8. Manolidis S, Donald PJ (1997) Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 80: 1373-1386
9. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F (1998) Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351: 793-796
10. Morton DL, Wen DR, Wong JH et al. (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127: 392-399
11. Veronesi U, Adamus J, Aubert C et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913-916
12. Kleeberg UR, Suciu S, Brocker EB et al. (2004) Final results of the EORTC 18871/DKG80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40: 390-402
13. Grob JJ, Dreno B, de La SP et al. (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351: 1905-1910
14. Pehamberger H, Soyer HP, Steiner A et al. (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16: 1425-1429
15. Kirkwood JM (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17
16. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670-1677
17. Lienard D, Eggermont AM, Koops HS et al. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9: 491-502
18. Seegenschmiedt MH, Keilholz L, Pieritz A et al. (1999) Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy. Strahlenther Onkol 175: 450-457
19. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP (1999) Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 9: 611-613
20. Rate WR, Solin LJ, Turrisi AT (1988) Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 15: 859-864
21. Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30: 515-520
22. Mornex F, Thomas L, Mohr P et al. (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13: 97-103
23. Avril MF, Aamdal S, Grob JJ et al. (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118-1125
24. Middleton MR, Grob JJ, Aaronson N et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166
25. Jungnelius U, Ringborg U, Aamdal S et al. (1998) Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 34: 1368-1374
26. Ridolfi R, Chiarion-Sileni V, Guida M et al. (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20: 1600-1607
27. Rosenberg SA, Lotze MT, Yang JC et al. (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl. Cancer Inst. 85: 622-632
28. Dudley ME, Wunderlich JR, Yang JC et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357
29. Berger TG, Schultz ES (2003) Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 276: 163-197
30. Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186: 1183-1187